StevenMFruchtmanMD
Hematology • New York, NYAssociate Professor of Hematology & Oncology, New York Medical College
Dr. Fruchtman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
863 Riverside Dr
Suite 1 Fw
New York, NY 10032Phone+1 201-310-1634Fax+1 212-996-8034
Education & Training
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1981 - 1983
SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 1977 - 1981
New York Medical CollegeClass of 1977
Certifications & Licensure
NY State Medical License 1978 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2003-2014
- Top Doctors: New York Metro Area Castle Connolly, 2002-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2007
- Join now to see all
Publications & Presentations
PubMed
- 150 citationsAllogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasiaDamiano Rondelli, Giovanni Barosi, Andrea Bacigalupo, Josef T. Prchal, Uday R. Popat
Blood. 2005-05-15 - 403 citationsTherapeutic recommendations in polycythemia vera based on polycythemia vera study group protocolsBerk Pd, Judith D. Goldberg, P B Donovan, Steven M. Fruchtman, N I Berlin
Seminars in Hematology. 1986-04-01 - 16 citationsThe Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First‐Line Hypomethylating Agents FailChristopher R. Cogle, Sandra E. Kurtin, Tanya G K Bentley, Michael S. Broder, Eunice Chang
The Oncologist. 2017-04-01
Abstracts/Posters
- Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)Steven M. Fruchtman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidin...Steven M. Fruchtman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial CancerMay 12th, 2023- Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial CancerMay 11th, 2023
- Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark GelderApril 6th, 2023
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
